Physician profile
Kathan Mehta
NPI 1427391887
$6,857.53
in general payments reported to CMS, 2019-2025
30 companies · $1,624 in 2025
The $1,624 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $440 · 2020: $4,127 · 2021: $517 · 2022: $125 · 2023: $24.64 · 2025: $1,624.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $930 · Consulting Fee: $650 · Education: $68.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $930.04 |
| Consulting Fee | $650.00 |
| Education | $68.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $2,820.80 | 2020 | |
| Blueprint Medicines Corporation | $1,306.25 | 2020 | |
| Daiichi Sankyo INC. | $817.02 | 2025 | Vanflyta, Enhertu |
| Astrazeneca Pharmaceuticals LP | $430.02 | 2019-2025 | Imfinzi |
| E.R. Squibb & Sons, L.L.C. | $267.65 | 2021-2025 | Opdivo |
| Novocure INC. | $146.20 | 2021 | |
| Genentech USA, INC. | $135.04 | 2019-2025 | Tecentriq |
| Glaxosmithkline, LLC. | $129.42 | 2025 | Ojjaara, Zejula, Jemperli |
| Beigene USA, INC. | $121.98 | 2021 | |
| Incyte Corporation | $102.46 | 2025 | Jakafi, Zynyz |
| Regeneron Healthcare Solutions, INC. | $100.94 | 2021 | |
| Exelixis INC. | $56.47 | 2025 | Cabometyx |
| Novartis Pharmaceuticals Corporation | $43.27 | 2022-2025 | |
| Geron Corporation | $41.74 | 2025 | Rytelo |
| Merck Sharp & Dohme LLC | $40.84 | 2025 | Keytruda, Lynparza, Welireg |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $37.65 | 2025 | Erleada |
| Pfizer INC. | $28.04 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.92 | 2025 | |
| Sobi, INC | $26.67 | 2025 | |
| Astellas Pharma US INC | $24.64 | 2023 | Padcev |
| Stemline Therapeutics INC. | $24.61 | 2025 | Orserdu |
| Abbvie INC. | $23.85 | 2025 | |
| Emd Serono, INC. | $22.56 | 2025 | |
| Alexion Pharmaceuticals, INC. | $22.08 | 2025 | Ultomiris |
| Tersera Therapeutics LLC | $17.18 | 2025 | Quzyttir |
| Sanofi-Aventis U.S. LLC | $14.50 | 2021 | |
| Celgene Corporation | $14.44 | 2025 | Reblozyl |
| Seagen INC. | $13.29 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathan Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.